Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 47

1.

Diabetes and differences in detection of incident invasive breast cancer.

Calip GS, Yu O, Boudreau DM, Shao H, Oratz R, Richardson SB, Gold HT.

Cancer Causes Control. 2019 May;30(5):435-441. doi: 10.1007/s10552-019-01166-2. Epub 2019 Apr 4.

PMID:
30949885
2.

Serial immunological parameters in a phase II trial of exemestane and low-dose oral cyclophosphamide in advanced hormone receptor-positive breast cancer.

Kwa M, Li X, Novik Y, Oratz R, Jhaveri K, Wu J, Gu P, Meyers M, Muggia F, Speyer J, Iwano A, Bonakdar M, Kozhaya L, Tavukcuoglu E, Budan B, Raad R, Goldberg JD, Unutmaz D, Adams S.

Breast Cancer Res Treat. 2018 Feb;168(1):57-67. doi: 10.1007/s10549-017-4570-4. Epub 2017 Nov 9.

PMID:
29124456
3.

INTRAVITREAL BEVACIZUMAB IN THE MANAGEMENT OF BREAST CANCER IRIS METASTASIS.

Seidman CJ, Finger PT, Silverman JS, Oratz R.

Retin Cases Brief Rep. 2017 Winter;11(1):47-50. doi: 10.1097/ICB.0000000000000285.

PMID:
26862924
4.

Clinical trial evidence of the antitumor activity of topical imiquimod for breast cancer skin metastases.

Adams S, Novik Y, Oratz R, Axelrod D, Speyer J, Tiersten A, Goldberg JD, Bhardwaj N, Unutmaz D, Demaria S, Formenti S.

J Clin Oncol. 2014 Oct 1;32(28):3204-5. doi: 10.1200/JCO.2014.56.1282. Epub 2014 Aug 4. No abstract available.

PMID:
25092780
5.

Cancer risk assessment using genetic panel testing: considerations for clinical application.

Hiraki S, Rinella ES, Schnabel F, Oratz R, Ostrer H.

J Genet Couns. 2014 Aug;23(4):604-17. doi: 10.1007/s10897-014-9695-6. Epub 2014 Mar 7.

PMID:
24599651
6.

Genetic variants associated with breast cancer risk for Ashkenazi Jewish women with strong family histories but no identifiable BRCA1/2 mutation.

Rinella ES, Shao Y, Yackowski L, Pramanik S, Oratz R, Schnabel F, Guha S, LeDuc C, Campbell CL, Klugman SD, Terry MB, Senie RT, Andrulis IL, Daly M, John EM, Roses D, Chung WK, Ostrer H.

Hum Genet. 2013 May;132(5):523-36. doi: 10.1007/s00439-013-1269-4. Epub 2013 Jan 25.

7.

Cost-effectiveness of 21-gene assay in node-positive, early-stage breast cancer.

Vanderlaan BF, Broder MS, Chang EY, Oratz R, Bentley TG.

Am J Manag Care. 2011;17(7):455-64.

8.

Physician survey of the effect of the 21-gene recurrence score assay results on treatment recommendations for patients with lymph node-positive, estrogen receptor-positive breast cancer.

Oratz R, Kim B, Chao C, Skrzypczak S, Ory C, Bugarini R, Broder M.

J Oncol Pract. 2011 Mar;7(2):94-9. doi: 10.1200/JOP.2010.000046.

9.

Phase II trial of dacarbazine and thalidomide for the treatment of metastatic melanoma.

Ott PA, Chang JL, Oratz R, Jones A, Farrell K, Muggia F, Pavlick AC.

Chemotherapy. 2009;55(4):221-7. doi: 10.1159/000219435. Epub 2009 May 19.

PMID:
19451711
10.

Phase I study of bryostatin 1, a protein kinase C modulator, preceding cisplatin in patients with refractory non-hematologic tumors.

Pavlick AC, Wu J, Roberts J, Rosenthal MA, Hamilton A, Wadler S, Farrell K, Carr M, Fry D, Murgo AJ, Oratz R, Hochster H, Liebes L, Muggia F.

Cancer Chemother Pharmacol. 2009 Sep;64(4):803-10. doi: 10.1007/s00280-009-0931-y. Epub 2009 Feb 17.

11.

Feasibility and cardiac safety of pegylated liposomal doxorubicin plus trastuzumab in heavily pretreated patients with recurrent HER2-overexpressing metastatic breast cancer.

Andreopoulou E, Gaiotti D, Kim E, Volm M, Oratz R, Freedberg R, Downey A, Vogel CL, Chia S, Muggia F.

Clin Breast Cancer. 2007 Aug;7(9):690-6.

PMID:
17919349
12.

Impact of a commercial reference laboratory test recurrence score on decision making in early-stage breast cancer.

Oratz R, Paul D, Cohn AL, Sedlacek SM.

J Oncol Pract. 2007 Jul;3(4):182-6. doi: 10.1200/JOP.0742001.

13.

A comparison of survival rates for treatment of melanoma metastatic to the brain.

Stone A, Cooper J, Koenig KL, Golfinos JG, Oratz R.

Cancer Invest. 2004;22(4):492-7.

PMID:
15565805
14.

Intratumoral cisplatin/adrenaline injectable gel for the treatment of patients with cutaneous and soft tissue metastases of malignant melanoma.

Oratz R, Hauschild A, Sebastian G, Schadendorf D, Castro D, Bröcker EB, Orenberg EK.

Melanoma Res. 2003 Feb;13(1):59-66.

PMID:
12569286
15.

Elective radiation therapy for high-risk malignant melanomas.

Cooper JS, Chang WS, Oratz R, Shapiro RL, Roses DF.

Cancer J. 2001 Nov-Dec;7(6):498-502.

PMID:
11769862
16.

Development of tumor-infiltrating lymphocytes in breast cancer after neoadjuvant paclitaxel chemotherapy.

Demaria S, Volm MD, Shapiro RL, Yee HT, Oratz R, Formenti SC, Muggia F, Symmans WF.

Clin Cancer Res. 2001 Oct;7(10):3025-30.

17.

Double-blind trial of a polyvalent, shed-antigen, melanoma vaccine.

Bystryn JC, Zeleniuch-Jacquotte A, Oratz R, Shapiro RL, Harris MN, Roses DF.

Clin Cancer Res. 2001 Jul;7(7):1882-7.

18.

Paclitaxel-induced apoptosis and mitotic arrest assessed by serial fine-needle aspiration: implications for early prediction of breast cancer response to neoadjuvant treatment.

Symmans WF, Volm MD, Shapiro RL, Perkins AB, Kim AY, Demaria S, Yee HT, McMullen H, Oratz R, Klein P, Formenti SC, Muggia F.

Clin Cancer Res. 2000 Dec;6(12):4610-7.

19.

Decrease in circulating tumor cells as an early marker of therapy effectiveness.

Bystryn JC, Albrecht J, Reynolds SR, Rivas MC, Oratz R, Shapiro RL, Roses DF, Harris MN, Conrad A.

Recent Results Cancer Res. 2001;158:204-7.

PMID:
11092048
20.

Identification of HLA-A*03, A*11 and B*07-restricted melanoma-associated peptides that are immunogenic in vivo by vaccine-induced immune response (VIIR) analysis.

Reynolds SR, Celis E, Sette A, Oratz R, Shapiro RL, Johnston D, Fotino M, Bystryn JC.

J Immunol Methods. 2000 Oct 20;244(1-2):59-67.

PMID:
11033019
21.

A phase II study of Didemnin B (NSC 325319) in advanced malignant melanoma: an Eastern Cooperative Oncology Group study (PB687).

Hochster H, Oratz R, Ettinger DS, Borden E.

Invest New Drugs. 1998-1999;16(3):259-63.

PMID:
10360606
22.

HLA-independent heterogeneity of CD8+ T cell responses to MAGE-3, Melan-A/MART-1, gp100, tyrosinase, MC1R, and TRP-2 in vaccine-treated melanoma patients.

Reynolds SR, Celis E, Sette A, Oratz R, Shapiro RL, Johnston D, Fotino M, Bystryn JC.

J Immunol. 1998 Dec 15;161(12):6970-6.

23.

Biologic activity of interleukin 1 (IL-1) alpha in patients with refractory malignancies.

Rosenthal MA, Dennis D, Liebes L, Furmanski P, Caron D, Garrison L, Wiprovnick J, Peace D, Oratz R, Speyer J, Chachoua A.

J Immunother. 1998 Sep;21(5):371-8.

PMID:
9789199
24.
25.

Identification of melanoma antigens that are immunogenic in humans and expressed in vivo.

Applebaum J, Reynolds S, Knispel J, Oratz R, Shapiro R, Bystryn JC.

J Natl Cancer Inst. 1998 Jan 21;90(2):146-9. Erratum in: J Natl Cancer Inst 1998 Jul 1;90(13):1017.

PMID:
9450575
26.

Stimulation of CD8+ T cell responses to MAGE-3 and Melan A/MART-1 by immunization to a polyvalent melanoma vaccine.

Reynolds SR, Oratz R, Shapiro RL, Hao P, Yun Z, Fotino M, Vukmanović S, Bystryn JC.

Int J Cancer. 1997 Sep 17;72(6):972-6.

27.

Effect of prolonged topotecan infusion on topoisomerase 1 levels: a phase I and pharmacodynamic study.

Hochster H, Liebes L, Speyer J, Sorich J, Taubes B, Oratz R, Wernz J, Chachoua A, Blum RH, Zeleniuch-Jacquotte A.

Clin Cancer Res. 1997 Aug;3(8):1245-52.

28.

Use of vaccines in treatment of malignant melanoma.

Bystryn JC, Shapiro RL, Harris M, Roses DF, Oratz R.

Clin Dermatol. 1996 Jul-Aug;14(4):337-41. Review. No abstract available.

PMID:
8862911
29.

Phase II trial of paclitaxel and cisplatin in women with advanced breast cancer: an active regimen with limiting neurotoxicity.

Wasserheit C, Frazein A, Oratz R, Sorich J, Downey A, Hochster H, Chachoua A, Wernz J, Zeleniuch-Jacquotte A, Blum R, Speyer J.

J Clin Oncol. 1996 Jul;14(7):1993-9. Erratum in: J Clin Oncol 1996 Dec;14(12):3175.

PMID:
8683229
30.

Effect of DETOX as an adjuvant for melanoma vaccine.

Schultz N, Oratz R, Chen D, Zeleniuch-Jacquotte A, Abeles G, Bystryn JC.

Vaccine. 1995 Apr;13(5):503-8.

PMID:
7639018
31.

Improved survival of patients with melanoma with an antibody response to immunization to a polyvalent melanoma vaccine.

Miller K, Abeles G, Oratz R, Zeleniuch-Jacquotte A, Cui J, Roses DF, Harris MN, Bystryn JC.

Cancer. 1995 Jan 15;75(2):495-502.

PMID:
7812920
32.

Phase Ib trial of granulocyte-macrophage colony-stimulating factor combined with murine monoclonal antibody R24 in patients with metastatic melanoma.

Chachoua A, Oratz R, Liebes L, Alter RS, Felice A, Peace D, Vilcek J, Blum RH.

J Immunother Emphasis Tumor Immunol. 1994 Aug;16(2):132-41.

PMID:
7804528
33.

Monocyte activation following systemic administration of granulocyte-macrophage colony-stimulating factor.

Chachoua A, Oratz R, Hoogmoed R, Caron D, Peace D, Liebes L, Blum RH, Vilcek J.

J Immunother Emphasis Tumor Immunol. 1994 Apr;15(3):217-24.

PMID:
8032545
34.

Phase I trial of low-dose continuous topotecan infusion in patients with cancer: an active and well-tolerated regimen.

Hochster H, Liebes L, Speyer J, Sorich J, Taubes B, Oratz R, Wernz J, Chachoua A, Raphael B, Vinci RZ, et al.

J Clin Oncol. 1994 Mar;12(3):553-9.

PMID:
8120553
35.

Pharmacokinetics of the cardioprotector ADR-529 (ICRF-187) in escalating doses combined with fixed-dose doxorubicin.

Hochster H, Liebes L, Wadler S, Oratz R, Wernz JC, Meyers M, Green M, Blum RH, Speyer JL.

J Natl Cancer Inst. 1992 Nov 18;84(22):1725-30.

PMID:
1433357
36.

Modulation of monocyte functions by muramyl tripeptide phosphatidylethanolamine in a phase II study in patients with metastatic melanoma.

Liebes L, Walsh CM, Chachoua A, Oratz R, Richards D, Hochster H, Peace D, Marino D, Alba S, Le Sher D, et al.

J Natl Cancer Inst. 1992 May 6;84(9):694-9.

PMID:
1569602
37.

Relationship between immune response to melanoma vaccine immunization and clinical outcome in stage II malignant melanoma.

Bystryn JC, Oratz R, Roses D, Harris M, Henn M, Lew R.

Cancer. 1992 Mar 1;69(5):1157-64.

PMID:
1739915
38.

Phase I study of doxorubicin, ICRF-187 and granulocyte/macrophage-colony-stimulating factor.

Walsh C, Blum RH, Oratz R, Goldenberg A, Downey A, Speyer JL.

J Cancer Res Clin Oncol. 1992;118(1):61-6.

PMID:
1729261
39.

Immunotherapy of malignant melanoma.

Oratz R, Bystryn JC.

Dermatol Clin. 1991 Oct;9(4):669-82. Review.

PMID:
1718648
40.

Lack of effect of cyclophosphamide on the immunogenicity of a melanoma antigen vaccine.

Oratz R, Dugan M, Roses DF, Harris MN, Speyer JL, Hochster H, Weissman J, Henn M, Bystryn JC.

Cancer Res. 1991 Jul 15;51(14):3643-7.

41.

Survival with regional and distant metastases from cutaneous malignant melanoma.

Roses DF, Karp NS, Oratz R, Dubin N, Harris MN, Speyer J, Boyd A, Golomb FM, Ransohoff J, Dugan M, et al.

Surg Gynecol Obstet. 1991 Apr;172(4):262-8.

PMID:
2006449
42.

Antimelanoma monoclonal antibody-ricin A chain immunoconjugate (XMMME-001-RTA) plus cyclophosphamide in the treatment of metastatic malignant melanoma: results of a phase II trial.

Oratz R, Speyer JL, Wernz JC, Hochster H, Meyers M, Mischak R, Spitler LE.

J Biol Response Mod. 1990 Aug;9(4):345-54.

PMID:
2395000
43.

Induction of tumor-infiltrating lymphocytes in human malignant melanoma metastases by immunization to melanoma antigen vaccine.

Oratz R, Cockerell C, Speyer JL, Harris M, Roses D, Bystryn JC.

J Biol Response Mod. 1989 Aug;8(4):355-8.

PMID:
2754436
44.

Immunogenicity of a polyvalent melanoma antigen vaccine in humans.

Bystryn JC, Oratz R, Harris MN, Roses DF, Golomb FM, Speyer JL.

Cancer. 1988 Mar 15;61(6):1065-70.

PMID:
3342366
45.

Treatment of metastatic malignant melanoma with dacarbazine and cisplatin.

Oratz R, Speyer JL, Green M, Blum R, Wernz JC, Muggia FM.

Cancer Treat Rep. 1987 Sep;71(9):877-8. No abstract available.

PMID:
3621224
46.

Carcinoid syndrome from a tumor of Meckel's diverticulum.

Green M, Oratz R, Muggia FM.

Am J Med. 1987 Jul;83(1):184-6. No abstract available.

PMID:
3605172
47.

Humoral mediator of antigenic competition demonstrated in vivo.

Zolla-Pazner S, Koehne C, Oratz R.

Int Arch Allergy Appl Immunol. 1979;59(3):349-56.

PMID:
447413

Supplemental Content

Support Center